Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting
Zymeworks Inc. (NYSE: ZYME) had its price target raised by analysts at HC Wainwright from $12.00 to $13.00. They now have a "neutral" rating on the stock.
Analysts Just Shipped A Captivating Upgrade To Their Zymeworks Inc. (NASDAQ:ZYME) Estimates [Yahoo! Finance]
Zymeworks Inc. (NYSE: ZYME) had its price target raised by analysts at Citigroup Inc. from $18.00 to $19.00. They now have a "buy" rating on the stock.